These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 747086)

  • 21. Fluorouracil, methyl-CCNU and vincristine in cancer of the colon.
    Falkson G; Falkson HC
    Cancer; 1976 Oct; 38(4):1468-70. PubMed ID: 791472
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The nitrosoureas--thoughts for the future.
    Carter SK; Wasserman TH
    Cancer Treat Rep; 1976 Jun; 60(6):807-11. PubMed ID: 954014
    [No Abstract]   [Full Text] [Related]  

  • 23. Combined actions of 5-fluorouracil and 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea on human colonic carcinoma cells in vitro.
    Sutton JE; Roos IA; Hillcoat BL
    Cancer Res; 1982 Dec; 42(12):5172-5. PubMed ID: 7139620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I trial of combination methotrexate and methyl-CCNU in patients with advanced neoplastic diseases.
    Lehane DE; Lane M; Tranum B; Costanzi J; Padilla F
    Cancer Treat Rep; 1977 Aug; 61(5):889-91. PubMed ID: 329982
    [No Abstract]   [Full Text] [Related]  

  • 25. Methyl-CCNU (NSC-95441) in advanced colorectal carcinoma after failure of 5-fluorouracil (NSC-19893) therapy.
    Cedermark BJ; Didolkar MS; Elias EG
    Cancer Treat Rep; 1976 Mar; 60(3):235-8. PubMed ID: 769977
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of advanced colorectal cancer with a combination of 5-fluorouracil and methyl-CCNU.
    Fischetti MR; Carey RW; Weitzman SA; Kaufman S; Kelley RM; Sohier WD
    Med Pediatr Oncol; 1978; 4(3):277-8. PubMed ID: 683130
    [No Abstract]   [Full Text] [Related]  

  • 27. Baker's antifol in combination with 5-fluorouracil and methyl-CCNU in the treatment of metastatic colorectal cancer: a Southwest Oncology Group Study (Protocol 7764).
    Shaw MT; Bonnet JD; Wilson H; Heilbrun LK
    Cancer Treat Rep; 1980; 64(2-3):247-50. PubMed ID: 7407758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II study of oral methyl-CCNU and prednisone in previously treated alkylating agent-resistant multiple myeloma.
    Tornyos K; Silberman H; Solomon A
    Cancer Treat Rep; 1977 Aug; 61(5):785-7. PubMed ID: 329977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Iv methyl-CCNU and ftorafur with or without methanol-extracted residue of BCG for metastatic adenocarcinoma of the colon.
    Diggs CH; Wiernik PH; Smyth AC
    Cancer Treat Rep; 1977 Nov; 61(8):1581-3. PubMed ID: 336200
    [No Abstract]   [Full Text] [Related]  

  • 30. Acute leukemia after adjuvant therapy of gastrointestinal cancer with semustine (methyl-CCNU).
    N Engl J Med; 1984 Apr; 310(16):1057-8. PubMed ID: 6708984
    [No Abstract]   [Full Text] [Related]  

  • 31. Case report: acute leukemia after semustine (methyl-CCNU) therapy.
    Uphouse WJ; Oishi N
    Cancer Treat Rep; 1982 Jul; 66(7):1593-4. PubMed ID: 6953997
    [No Abstract]   [Full Text] [Related]  

  • 32. Phase II study of methyl-CCNU in the treatment of advanced pancreatic carcinoma.
    Moertel CG; Douglass HO; Hanley J; Carbone PP
    Cancer Treat Rep; 1976 Nov; 60(11):1659-61. PubMed ID: 1035508
    [No Abstract]   [Full Text] [Related]  

  • 33. Phase II trial of methyl-CCNU, vincristine, 5-fluorouracil, and streptozotocin (MOF-Strep) in patients with disseminated pancreatic carcinoma.
    Sordillo PP; Magill GB
    Am J Clin Oncol; 1982 Jun; 5(3):277-9. PubMed ID: 6282110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU).
    Boice JD; Greene MH; Killen JY; Ellenberg SS; Keehn RJ; McFadden E; Chen TT; Fraumeni JF
    N Engl J Med; 1983 Nov; 309(18):1079-84. PubMed ID: 6353233
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methyl-CCNU and ftorafur in treatment of rectosigmoidal tumors and ftorafur capsules in treatment of colorectal tumors.
    Mechl Z; Malír
    Recent Results Cancer Res; 1981; 79():59-64. PubMed ID: 6795699
    [No Abstract]   [Full Text] [Related]  

  • 36. Phase II study of methyl-CCNU (NSC-95441) in advanced gastrointestinal cancer.
    Engstrom PF; Catalano RB; Creech RH
    Cancer Treat Rep; 1976 Mar; 60(3):285-7. PubMed ID: 1260784
    [No Abstract]   [Full Text] [Related]  

  • 37. Phase I--II study of the combination of 5-FU, doxorubicin, mitomycin, and semustine (FAMMe) in the treatment of adenocarcinoma of the stomach, gastroesophageal junction, and pancreas.
    Karlin DA; Stroehlein JR; Bennetts RW; Jones RD; Heifetz LJ; Mahal PS
    Cancer Treat Rep; 1982 Aug; 66(8):1613-7. PubMed ID: 7105051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II study of mitolactol and semustine combination chemotherapy for advanced malignant melanoma.
    Creagan ET; Ahmann DL; Schutt AJ; Green SJ
    Cancer Treat Rep; 1982 Jun; 66(6):1425-6. PubMed ID: 7083244
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Leukemia after adjuvant chemotherapy with semustine (methyl-CCNU)--evidence of a dose-response effect.
    Boice JD; Greene MH; Killen JY; Ellenberg SS; Fraumeni JF; Keehn RJ; McFadden E; Chen TT; Stablein D
    N Engl J Med; 1986 Jan; 314(2):119-20. PubMed ID: 3941685
    [No Abstract]   [Full Text] [Related]  

  • 40. [Combination chemotherapy of transplanted rat leukemia L 5222 with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and cyclophosphamide (CPA) as well as with methyl-CCNU and CPA (author's transl)].
    Zeller WJ; Berger M
    Arzneimittelforschung; 1981; 31(2):303-5. PubMed ID: 7194646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.